As our Numerof 2022 Global Pharma Outlook infographic illustrates, this year’s story for pharmaceutical manufacturers will be about continuing to adapt to pressures on price and demands for value while dealing with the aftereffects of the pandemic.

Across the globe, engagement with stakeholders will require new approaches as systems and practices continue to limit representative access in some therapeutic areas. This will force continued innovation – not just in your engagement efforts, but organizationally, in the way you structure and support your commercial approach. The need for new and different ways to engage with healthcare executives, physicians, and payers will not be going away anytime soon.

Ongoing efforts to accelerate drug development mean companies may face competition more quickly than before. In light of ongoing supply chain challenges, it is expected that regulators will continue tough enforcement, including coordinated global supply chain oversight and data requirements. In the EU, expect direct pricing agreements, price controls, as well as reference and risk-based pricing, and access limits. In the U.S., political pressure for government intervention to control drug prices is at a new high. What happens next on the legislative front may dramatically change the industry for years to come.

Payer, PBM and employer pushback on drug prices will continue to intensify, as will efforts to create new reimbursement approaches. Still, collaborations by manufacturers with payers and providers on data sharing and real-world evidence will grow. Consumers will get even more engaged as they pay more of the cost, although adherence will continue to be both a major challenge and opportunity.

Access restrictions will continue in healthcare delivery and with payers. Anticipated challenges include continued efforts to centralize buying decisions in cross functional committees, and additional restrictions regarding customer engagement. U.S. integrated delivery networks (IDNs) will expand their influence over outpatient prescribing, as they move to value-based payments and go at-risk for patient outcomes. Systems will try to influence product decision-making as they try to gain control over variation in cost and quality.

Given this outlook, what’s next?  We recommend these key action steps:

At Numerof & Associates, we help pharmaceutical manufacturers achieve these key action steps for success in today’s evolving healthcare landscape. From competitive strategy and ensuring evidence to demonstrate value to commercial model innovation and implementation we have solutions. Read more about our perspectives and solutions for the pharmaceutical industry and see our case studies.

Need critical insights across the healthcare sector? Check out our 2022 outlook infographics for healthcare deliverymedical devices and diagnostics, and payers.